G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
0 hedge funds and large institutions have $0 invested in G1 Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 88 closing their positions.
100% less funds holding
Funds holding: 88 → 0 (-88)
100% less capital invested
Capital invested by funds: $45.5M → $0 (-$45.5M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 88
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.03M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.68M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$3.11M |
| 4 |
Renaissance Technologies
New York
|
-$2.84M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.46M |
GTHX Hedge Fund Activity: Q3 2024 in Review
0 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2024, worth a combined $0 — down 100% from $45.5M a quarter earlier.
Sellers outnumbered buyers: 88 funds closed out of GTHX and 0 opened new positions — a net loss of 88 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $7.03M sold.
- 0 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2024, down from 88 in Q2 2024.
- Funds reported $0 of G1 Therapeutics, Inc. Common Stock stock for Q3 2024, down 100% quarter-over-quarter.
- 0 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2024 and 88 closed out, a net change of -88 holders.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2024 was BlackRock, an estimated $7.03M sold.
Based on aggregated 13F filings for Q3 2024.